Taysha Gene Therapies, Inc. Appoints Timothy J. Douros as Chief Legal Officer and Corporate Secretary and Tracy M. Porter as Chief People Officer
January 26, 2021 at 07:00 am EST
Share
Taysha Gene Therapies, Inc. announced new additions to its leadership team with the appointments of Timothy J. Douros, J.D., as Chief Legal Officer and Corporate Secretary and Tracy M. Porter, M.Ed., SPHR, as Chief People Officer. Mr. Douros will lead all aspects of the company's legal organization. Ms. Porter will oversee all aspects of human resources, including operations, talent acquisition and employee development. Mr. Douros brings over 25 years of legal experience. Prior to joining Taysha, he served as Senior Vice President, General Counsel at Bluebird Bio, Inc. Ms. Porter joins Taysha with nearly 30 years as a human resources executive. She most recently served as Vice President, Head of Human Resources at Audentes Therapeutics, where she developed.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company, which is focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. The Companyâs lead clinical program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder. The Company is evaluating TSHA-102 in the REVEALPhase I/II adolescent and adult clinical trial, which is a first-in-human, open-label, randomized, dose escalation and dose-expansion, multicenter study evaluating the safety and preliminary efficacy of TSHA-102 in female patients aged 12-years and older with Rett syndrome. It has acquired a worldwide right to a clinical-stage, intrathecally dosed AAV9 gene therapy program, TSHA-120, for the treatment of giant axonal neuropathy (GAN). It received orphan drug designation from the European Commission for TSHA-120 for the treatment of GAN.
TAYSHA GENE THERAPIES, INC. 
